The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Sacroiliitis Treatment Market Over The 2026–2030 Period?
The sacroiliitis treatment market has demonstrated significant expansion in recent years. This market is projected to increase from $1.77 billion in 2025 to $1.9 billion in 2026, showing a compound annual growth rate (CAGR) of 7.4%. Historically, this growth can be attributed to several factors, including the increasing occurrence of inflammatory spinal disorders, the broader application of diagnostic imaging, a better understanding of sacroiliac joint pathology, the proliferation of pain management clinics, and the availability of advanced pharmacological therapies.
The sacroiliitis treatment market is set to experience significant expansion over the next few years. By 2030, it is forecast to grow to $2.5 billion, demonstrating a compound annual growth rate (CAGR) of 7.1%. This projected growth during the forecast period is primarily due to the increasing acceptance of biologic drugs, a rising need for minimally invasive pain therapies, the proliferation of outpatient orthopedic procedures, enhanced integration of digital diagnostics, and a heightened emphasis on long-term mobility restoration. Key developments expected within this period involve the expanding use of image-guided diagnostic methods, increased implementation of minimally invasive SI joint fusion, a growing inclination towards biologic and targeted therapies, the broadening application of radiofrequency-based pain management, and a stronger focus on tailored treatment plans.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24688&type=smp
What Primary Drivers Are Shaping The Sacroiliitis Treatment Market?
The sacroiliitis treatment market is anticipated to expand due to the increasing incidence of joint disorders. These conditions, which involve pain, inflammation, stiffness, and impaired movement in the joints, arise from various factors including injury, aging, autoimmune diseases, or infections. The rise in joint disorder cases is largely attributed to aging populations experiencing natural wear and tear on their joints, leading to a higher prevalence of conditions such as osteoarthritis and other degenerative joint diseases. Sacroiliitis treatment proves beneficial for joint disorders by helping to reduce inflammation and pain in the sacroiliac joints, consequently improving mobility and overall joint function, which can alleviate symptoms and prevent further joint damage. For example, in February 2024, data from Arthritis Australia, an Australia-based non-profit organization, indicated that by 2025, osteoarthritis (OA) is projected to affect 2.35 million Australians, making up 57% of the total arthritis population and establishing it as the country’s most common form of arthritis. By 2040, the number of Australians with OA is expected to increase to 3.11 million, a 32% rise from 2025, corresponding to an additional 762,515 people living with OA in Australia compared to 2025. Therefore, the escalating prevalence of joint disorders is a key factor driving the growth of the sacroiliitis treatment market.
Which Segment Categories Are Included In The Sacroiliitis Treatment Market Segment Analysis?
The sacroiliitis treatment market covered in this report is segmented –
1) By Type: Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation, Electrical Stimulation
2) By Diagnosis: Imaging Tests, Physical Examination, Laboratory Tests, Other Diagnosis
3) By Route Of Administration: Oral, Injectable, Topical
4) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Care Settings
Subsegments:
1) By Medications: NSAIDs (Nonsteroidal Anti-Inflammatory Drugs), Corticosteroids, Disease-Modifying Antirheumatic Drugs (DMARDs), Biologic Agents, Analgesics
2) By Joint Injections: Corticosteroid Injections, Platelet-Rich Plasma (PRP) Injections, Hyaluronic Acid Injections, Prolotherapy
3) By Joint Fusion: Minimally Invasive SI Joint Fusion, Open SI Joint Fusion, Robotic-Assisted Fusion Techniques, Posterior Approach Fusion, Lateral Approach Fusion
4) By Radiofrequency Denervation: Conventional Radiofrequency Ablation, Cooled Radiofrequency Ablation, Pulsed Radiofrequency Ablation
5) By Electrical Stimulation: Transcutaneous Electrical Nerve Stimulation (TENS), Spinal Cord Stimulation (SCS), Peripheral Nerve Stimulation (PNS)
What Trends Are Affecting The Growth Of The Sacroiliitis Treatment Market?
Leading companies in the sacroiliitis treatment market prioritize obtaining regulatory approvals to expedite the introduction of innovative therapies, secure market entry, and enhance their competitive standing. Regulatory approvals signify formal authorization from government health agencies, confirming that medical treatments are safe and effective for public use. As an illustration, in December 2023, Spinal Simplicity, a US-based medical equipment manufacturer, secured FDA 510(k) clearance for its Liberty-SI Lateral Implant System, a minimally invasive, transfixing device crafted for sacroiliac joint fusion in patients afflicted with conditions such as sacroiliac disruptions and degenerative sacroiliitis. This system employs a lateral technique, involving the insertion of one or two titanium implants through the ilium and across the SI joint into the sacrum to provide stabilization and fusion. The implants are characterized by a central threaded body with deployable wings and compressive elements, are offered in various sizes, and are coated with hydroxyapatite to foster better integration. This procedure aims to be safer and less intrusive, potentially decreasing anesthesia duration and leading to improved patient outcomes.
Who Are The Active Companies Shaping The Sacroiliitis Treatment Market?
Major companies operating in the sacroiliitis treatment market are Pfizer Inc, Johnson And Johnson, AbbVie Inc, Novartis AG, Eli Lilly And Company, Boehringer Ingelheim International GmbH, Amgen Inc, Biogen Inc, Sandoz Group AG, UCB SA, Hikma Pharmaceuticals PLC, Samsung Bioepis Co Ltd, Lupin Limited, Zydus Lifesciences Limited, Celltrion Healthcare Co Ltd, Torrent Pharmaceuticals Limited, Globus Medical, Orthofix Medical Inc, Coherus BioSciences Inc, SI BONE Inc, Medtronic plc
Get The Full Sacroiliitis Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/sacroiliitis-treatment-global-market-report
Which Region Leads The Sacroiliitis Treatment Market In Terms Of Market Share?
North America was the largest region in the sacroiliitis treatment market in2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sacroiliitis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Sacroiliitis Treatment Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/sacroiliitis-treatment-global-market-report
Browse Through More Reports Similar to the Global Sacroiliitis Treatment Market 2026, By The Business Research Company
Diverticulitis Disease Market Report 2026
https://www.thebusinessresearchcompany.com/report/diverticulitis-disease-global-market-report
Neutropenia Biologic Drug Treatments Market Report
Psoriatic Arthritis Treatments Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model